Latest Period
Q4 2025
Security Snapshot
Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) Institutional Ownership
CUSIP: 034569103
13F Institutional Holders and Ownership History from Q2 2021 to Q4 2025
Institutions Reporting
16
Shares (Excl. Options)
6,741,386
Price
$1.01
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- ANEB on OTC
- Shares outstanding
- 41,587,315
- Price per share
- $0.87
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 6,741,386
- Total reported value
- $6,808,914
- % of total 13F portfolios
- 0%
- Share change
- -11,077
- Value change
- -$68,403
- Number of holders
- 16
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ANEB - Anebulo Pharmaceuticals, Inc. - Common Stock is tracked under CUSIP 034569103.
- 16 institutions reported positions in Q4 2025.
- 3 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 20 to 16 between Q3 2025 and Q4 2025.
- Reported value moved from $55,549,711 to $6,808,914.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 16 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 034569103?
CUSIP 034569103 identifies ANEB - Anebulo Pharmaceuticals, Inc. - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 034569103:
Significant Owners of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| English Aron R. | 51% | 0% | $25,877,258 | 21,929,880 | 0% | Aron R. English | 24 Feb 2025 | |
| Nantahala Capital Management, LLC | 8.5% | -1.1% | $3,582,872 | 3,547,398 | 0% | Nantahala Capital Management, LLC | 31 Dec 2025 | |
| MANGROVE PARTNERS IM, LLC | 6.2% | $2,979,797 | 2,525,252 | Mangrove Partners IM, LLC | 31 Dec 2024 |
As of 31 Dec 2025, 16 institutional investors reported holding 6,741,386 shares of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB). This represents 16% of the company’s total 41,587,315 outstanding shares.
Top 21 Institutional Shareholders
The largest institutional shareholders of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) together control 53% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 7.3% | 3,036,325 | 0% | 0.18% | $3,066,688 |
| MANGROVE PARTNERS IM, LLC | 6.1% | 2,525,252 | 0% | 0.21% | $2,550,505 |
| VANGUARD GROUP INC | 1% | 435,821 | +42% | 0% | $440,179 |
| MORGAN STANLEY | 0.96% | 399,404 | 0% | 0% | $403,398 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.39% | 160,760 | -7.7% | 0% | $162,482 |
| Rangeley Capital, LLC | 0.12% | 50,000 | +150% | 0.04% | $50,500 |
| RENAISSANCE TECHNOLOGIES LLC | 0.06% | 25,098 | -12% | 0% | $25,349 |
| CITADEL ADVISORS LLC | 0.06% | 24,239 | 0% | $24,481 | |
| BlackRock, Inc. | 0.06% | 23,790 | -1.1% | 0% | $24,028 |
| NORTHERN TRUST CORP | 0.05% | 21,994 | -9.8% | 0% | $22,214 |
| Ikarian Capital, LLC | 0.04% | 17,736 | -89% | 0% | $17,913 |
| STATE STREET CORP | 0.03% | 12,768 | 0% | 0% | $12,896 |
| Tower Research Capital LLC (TRC) | 0.01% | 3,230 | +85% | 0% | $3,262 |
| UBS Group AG | 0.01% | 2,334 | +961% | 0% | $2,357 |
| JPMORGAN CHASE & CO | 0.01% | 2,253 | +5.4% | 0% | $2,276 |
| BANK OF AMERICA CORP /DE/ | 0% | 382 | -57% | 0% | $386 |
| BARCLAYS PLC | 0% | 0 | -100% | $0 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 0% | 0 | -100% | $0 | |
| XTX Topco Ltd | 0% | 0 | -100% | $0 | |
| CITIGROUP INC | 0% | 0 | -100% | $0 | |
| 22NW, LP | 37% | 15,467,300 | 0% | $84,760,804 |
Institutional Holders of Anebulo Pharmaceuticals, Inc. - Common Stock (ANEB) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 6,741,386 | $6,808,914 | -$68,403 | $1.01 | 16 |
| 2025 Q3 | 22,219,763 | $55,549,711 | -$356,433 | $2.50 | 20 |
| 2025 Q2 | 22,591,946 | $32,532,431 | -$34,513 | $1.44 | 18 |
| 2025 Q1 | 22,618,242 | $29,403,638 | +$39,506 | $1.30 | 18 |
| 2024 Q4 | 22,570,347 | $37,311,560 | +$24,974,043 | $1.68 | 15 |
| 2024 Q3 | 7,343,734 | $14,173,448 | +$69,135 | $1.93 | 13 |
| 2024 Q2 | 7,307,778 | $19,950,292 | +$326 | $2.73 | 12 |
| 2024 Q1 | 7,306,365 | $20,969,328 | +$85,916 | $2.87 | 14 |
| 2023 Q4 | 7,278,993 | $17,615,165 | +$183,945 | $2.42 | 13 |
| 2023 Q3 | 7,050,491 | $21,560,562 | +$51,779 | $3.06 | 11 |
| 2023 Q2 | 7,031,883 | $16,498,373 | +$460,020 | $2.35 | 11 |
| 2023 Q1 | 6,836,130 | $19,834,339 | -$508,787 | $2.90 | 9 |
| 2022 Q4 | 7,046,307 | $17,074,708 | -$15,992 | $2.42 | 12 |
| 2022 Q3 | 6,842,912 | $19,161,000 | +$6,062,684 | $2.80 | 10 |
| 2022 Q2 | 4,677,847 | $24,324,000 | +$2,192,344 | $5.20 | 8 |
| 2022 Q1 | 4,190,412 | $29,539,000 | -$21,602 | $7.02 | 8 |
| 2021 Q4 | 4,193,307 | $25,818,000 | +$61,833 | $6.21 | 8 |
| 2021 Q3 | 4,183,214 | $27,472,000 | -$109,295 | $6.58 | 7 |
| 2021 Q2 | 4,199,813 | $28,670,000 | +$28,670,000 | $6.85 | 8 |